'Even more existential was the decision about what to do with the clinical trial as Covid-19 swept through hospitals, putting many studies on hold. Many others in the industry stopped to think — and then found it hard to restart the trials. Within 24 hours, Immunocore committed to continuing no matter what. “This would have been life or death for the company,” she says.

To do so, they had to switch to telehealth fast, with no time to wait for guidance from the regulator. Immunocore had to rapidly come up with plans for every scenario, such as identifying which data was absolutely essential for time-pressed staff to enter, and what to do if a patient developed Covid. In June 2020, the trial ended up finishing enrolling patients on time.'

https://www.ft.com/content/f575e537-3d18-4aea-b19e-abb320a02b68